...
首页> 外文期刊>Pharmaceutical research >Folate receptor-mediated liposomal delivery of a lipophilic boron agent to tumor cells in vitro for neutron capture therapy.
【24h】

Folate receptor-mediated liposomal delivery of a lipophilic boron agent to tumor cells in vitro for neutron capture therapy.

机译:叶酸受体介导的脂质体脂质体在体外向肿瘤细胞的脂质体递送,用于中子捕获治疗。

获取原文
获取原文并翻译 | 示例

摘要

PURPOSE: This study was aimed at the in vitro evaluations of folate receptor (FR)-targeted liposomes as carriers for a lipophilic boron agent, K[nido-7-CH3(CH2)15-7,8-C2B9H11, in FR-overexpressing tumor cells for neutron capture therapy. METHODS: Large unilamellar vesicles (-200 nm in diameter) were prepared with the composition of egg PC/chol/K[nido-7-CH3(CH2)15-7,8-C2B9H11] (2:2:1, mol/mol), with an additional 0.5 mol % of folate-PEG-DSPE or PEG-DSPE added for the FR-targeted or nontargeted liposomal formulations, respectively. RESULTS: Boron-containing, FR-targeted liposomes readily bound to KB cells, an FR-overexpressing cell line, and were internalized via FR-mediated endocytosis. The boron uptake in cells treated with these liposomes was approximately 10 times greater compared with those treated with control liposomes. In contrast, FR-targeted and nontargeted liposomes showed no difference in boron delivery efficiency in F98 cells, which do not express the FR. The subcellular distribution of the boron compound in KB cells treated with the FR-targeted liposomes was investigated by cellular fractionation experiments, which showed that most of the boron compound was found in either the cytosol/endosomal or cell membrane fractions, indicating efficient internalization of the liposomal boron. CONCLUSION: FR-targeted liposomes incorporating the lipophilic boron agent, K[nido-7-CH3(CH2)15-7,8-C2B9H11], into its bilayer were capable of specific receptor binding and receptor-mediated endocytosis in cultured KB cells. Such liposomes warrant further investigations for use in neutron capture therapy.
机译:目的:这项研究旨在体外评估叶酸受体(FR)靶向脂质体作为亲脂性硼剂K [nido-7-CH3(CH2)15-7,8-C2B9H11的载体,在FR过表达中肿瘤细胞用于中子捕获治疗。方法:制备大单层囊泡(直径为-200 nm),其成分为卵PC / chol / K [nido-7-CH3(CH2)15-7,8-C2B9H11](2:2:1,mol / mol),另外分别为FR靶向或非靶向脂质体制剂添加了0.5 mol%的叶酸-PEG-DSPE或PEG-DSPE。结果:含硼,FR靶向脂质体易于与KB细胞(一种FR过表达的细胞系)结合,并通过FR介导的内吞作用被内化。与用对照脂质体处理的细胞相比,用这些脂质体处理的细胞吸收的硼大约高10倍。相反,在不表达FR的F98细胞中,靶向FR的脂质体和未靶向的脂质体在硼递送效率上没有差异。通过细胞分离实验研究了硼化合物在用FR靶向脂质体处理过的KB细胞中的亚细胞分布,这表明大多数硼化合物存在于细胞质/内膜或细胞膜组分中,表明该化合物的有效内在化。脂质体硼。结论:将脂溶性硼剂K [nido-7-CH3(CH2)15-7,8-C2B9H11]掺入FR靶向脂质体能够在培养的KB细胞中特异性受体结合和受体介导的内吞作用。此类脂质体需要进一步研究以用于中子捕获疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号